A literature review published in Hormone and Metabolic Research argues that glucagon-like peptide-1 receptor agonists and melanocortin-4 receptor agonists, increasingly combined into dual and triple agents, represent promising therapeutic innovations for obesity and type 2 diabetes. It is a survey of the field rather than new trial data, which matters for how much weight the conclusions can carry.

The drugs under discussion include semaglutide (sold as Ozempic, Wegovy and, in tablet form, Rybelsus), liraglutide, tirzepatide and setmelanotide. GLP-1 receptor agonists work on a gut hormone pathway that prompts insulin release and blunts appetite, while melanocortin-4 receptor agonists act through the central nervous system on the circuit that governs hunger and energy expenditure.

Two appetite pathways, one target

According to the review, GLP-1 receptor agonists such as semaglutide and liraglutide promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control. Liraglutide is also credited with reducing cardiovascular risk.

The melanocortin-4 route is the less familiar half of the story and the more interesting one. The authors report that MC4R agonists reduce appetite and increase energy expenditure centrally, with setmelanotide showing efficacy specifically in genetic obesity, a narrow population that most obesity drug coverage skips entirely.

Why the field went multi-receptor

The review's central theme is combination. Dual and triple agonists such as tirzepatide hit GLP-1, glucose-dependent insulinotropic polypeptide and glucagon receptors at once, which the authors say leads to enhanced metabolic outcomes.

That is the direction the whole pipeline has taken, and the reasoning is straightforward: appetite and glucose handling are regulated by several overlapping systems, so engaging one was always going to leave room on the table. Whether stacking receptors keeps paying off is the question the next decade of trials answers.

The pill problem

Adherence gets more attention here than it usually does in drug reviews, and deservedly so. The authors emphasize oral formulations, noting semaglutide is available in both injectable and oral forms and that oral drugs like Rybelsus improve long-term adherence.

A weekly injection is a real barrier for a lot of people, and a drug nobody keeps taking is not an effective drug. Framing formulation as a clinical variable rather than a marketing detail is the sharper move in this paper.

Limitations

This is a narrative literature review, not a trial and not a systematic meta-analysis, so it carries no new outcome data and no pooled effect sizes. The abstract states no numbers: no percentage weight loss, no HbA1c change, no head-to-head comparison between the two receptor classes.

The conclusion that these agents are promising is the authors' synthesis judgment, and setmelanotide's reported efficacy applies to genetic obesity rather than obesity generally.

Bottom line

The review concludes that GLP-1 and MC4R agonists, particularly as dual or triple agents, are promising for obesity and type 2 diabetes, and that oral formulations enhance convenience and adherence. What remains unsettled is how the two receptor classes compare directly, and whether combination agents hold their advantage over longer follow-up.